Sio Capital Management’s Context Therapeutics CNTX Stock Holding History

Sio Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.4M	Sell	917,922 -423,714	-32%	-$989K	0.34%	54
2025 Q4	$1.97M	Hold	1,341,636	–	–	0.31%	49
2025 Q3	$1.3M	Hold	1,341,636	–	–	0.33%	39
2025 Q2	$879K	Buy	1,341,636 +13,284	+1%	+$9.55K	0.34%	39
2025 Q1	$813K	Hold	1,328,352	–	–	0.24%	42
2024 Q4	$1.39M	Hold	1,328,352	–	–	0.39%	35
2024 Q3	$2.6M	Hold	1,328,352	–	–	1.03%	23
2024 Q2	$2.66M	Buy	+1,328,352	New	+$2.29M	0.72%	25

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Sio Capital Management's CNTX Position: Q1 2026 in Review

Sio Capital Management reduced its Context Therapeutics (CNTX) stake by 32% in Q1 2026, selling an estimated $989K and leaving 917,922 shares worth $2.4M. The position accounts for 0.34% of the portfolio, ranked #54.

Sio Capital Management first reported a position in CNTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.66M in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Sio Capital Management held 917,922 shares of Context Therapeutics worth $2.4M as of Q1 2026.
Sio Capital Management sold 423,714 Context Therapeutics shares in Q1 2026, an estimated $989K.
Context Therapeutics made up 0.34% of Sio Capital Management's portfolio in Q1 2026, its #54 holding.
Sio Capital Management first reported a position in Context Therapeutics in Q2 2024 and has held it in 8 quarters since.
Sio Capital Management's Context Therapeutics position peaked at $2.66M in Q2 2024.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.